Kristin Wynholds - Mar 1, 2023 Form 4 Insider Report for Better Therapeutics, Inc. (BTTX)

Role
Chief Product Officer
Signature
/s/ Mark Heinen, Attorney-in-Fact
Stock symbol
BTTX
Transactions as of
Mar 1, 2023
Transactions value $
$0
Form type
4
Date filed
4/21/2023, 06:13 PM
Previous filing
Dec 2, 2022
Next filing
Dec 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction BTTX Common Stock +Grant/Award $0 +101,450 +102.66% $0.00 200,269 Apr 5, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTTX Stock Option (Right to Buy) +Grant/Award $0 +101,450 $0.00 101,450 Mar 1, 2023 Common Stock 101,450 $1.14 Direct F2

Explanation of Responses:

Id Content
F1 The shares represent restricted stock units (each, an "RSU") granted on April 5, 2023, which vest as to 1/2 of the shares on March 24, 2024 and the remaining shares vest on March 24, 2025, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The stock option vests as to 1/4 of the shares subject to the stock option on March 1, 2024 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on March 1, 2023.